Regeneron sells $2 billion notes; steady supply expected; fund, ETF inflows rise

By Cristal Cody

Tupelo, Miss., Aug. 7 – The high-grade primary market stayed active on Friday with a two-part offering from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals sold $2 billion of fixed-rate senior notes (Baa3/BBB+) with both tranches pricing 20 basis points tighter than initial guidance.

Also on Friday, Standard Industries Inc. priced a $1.1 billion split-rated offering of senior notes due Jan. 15, 2031 (Ba2/BBB-) in a Rule 144A and Regulation S deal.

Deal volume is expected to remain steady in the week ahead with syndicate forecasts of about $25 billion to $30 billion of supply anticipated.

Meanwhile, overall investment-grade bond fund and ETF inflows rose to $10.14 billion for the past week ended Wednesday from $9.03 billion in the prior week, according to a BofA Securities, Inc. research note released Friday.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.